Mehrdad Abedi, M.D.
Department
Title
- Professor of Medicine
Reviews
UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Driving Directions
Primary Phone:
800-362-5566
916-734-5959
Additional Phone Numbers
Clinic Fax: 916-703-5265
Clinic Referral Phone: 916-703-5210
Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Philosophy of Care
Dr. Abedi believes in high quality, innovative, and compassionate care of his patients. Dr. Abedi believes in a team-based approach to patient care, utilizing expertise of nurses, pharmacists, social workers, and consultants to provide complete care for his patients.
Clinical Interests
Dr. Abedi's clinical interest is in the area of bone marrow transplantation and in the treatment of refractory/relapsed hematological malignancies and genetic disease. He is also interested in using cellular therapy for treatment of a variety of medical disorders.
Research/Academic Interests
Dr. Abedi's basic science research interest is in the area of hematopoietic stem cells and novel models of bone marrow transplantation, and also gene and cellular therapy.
Division
Hematology and Oncology
Center/Program Affiliation
Education
M.D., Tehran University of Medical Sciences, Tehran, Iran 1991
Internship: Internal Medicine, Yale University/Bridgeport Hospital, New Haven CT 1996-1999
Residency
Internal Medicine, Yale University/Bridgeport Hospital, New Haven CT 1999
Fellowships
Hematology/Oncology, Brown University, Roger Williams Medical Center, Providence RI 2001-2002
Hematology/Oncology, University of Massachusetts Medical Center, Worcester MA 1999-2001
Board Certifications
American Board of Internal Medicine,
Hematology Certification,
Professional Memberships
American Association of Immunologists
American Society for Blood and Marrow Transplantation
American Society of Clinical Oncology
American Society of Hematology
Southwest Oncology Group, Myeloma and Lymphoma Committees
Honors and Awards
Alpha Clinic Award, UCDH, 2017
Select Recent Publications
For a comprehensive list of Dr. Abedi's publications, please click here (opens new window).
Othman T, Moskoff BN, Esteghamat N, Hoeg RT, Rosenberg AS, Jonas BA, Abedi M, Richman C, Tuscano JM. Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas. Leuk Lymphoma. 2022 Jan;63(1):231-234. doi:10.1080/10428194.2021.1975190. Epub 2021 Sep 6. PMID:34486920.
Khuat LT, Vick LV, Dunai C, Collins CP, More SK, Le CT, Pai CS, Stoffel KM, Maverakis E, Canter RJ, Monjazeb AM, Longo DL, Abedi M, Choi E, Blazar BR, Dave M, Murphy WJ. Increased efficacy of dual proinflammatory cytokine blockade on acute GVHD while maintaining GVT effects. Blood. 2021 Dec 16;138(24):2583-2588. doi:10.1182/blood.2021011216. PMID:34424962.
Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Feng C, Dong J, Shen T, Milletti F, Rossi JM, Vezan R, Masouleh BK, Houot R. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021 Aug 7;398(10299):491-502. doi:10.1016/S0140-6736(21)01222-8. Epub 2021 Jun 4. PMID:34097852.
Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, O'Dwyer KM, Holmes H, Arellano ML, Ghobadi A, Pagel JM, Lin Y, Cassaday RD, Park JH, Abedi M, Castro JE, DeAngelo DJ, Malone AK, Mawad R, Schiller GJ, Rossi JM, Bot A, Shen T, Goyal L, Jain RK, Vezan R, Wierda WG. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021 Jul 8;138(1):11-22. doi:10.1182/blood.2020009098. PMID:33827116.
Tenold ME, Moskoff BN, Krishnan R, Rosenberg AS, Hoeg RT, Abedi M, Tuscano JM, Jonas BA. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center. Clin Lymphoma Myeloma Leuk. 2021 Jul;21(7):e611-e618. doi:10.1016/j.clml.2021.02.007. Epub 2021 Mar 2. PMID:33811007.
Jonas BA, Fisch SC, Rosenberg AS, Hoeg RT, Tuscano JM, Abedi M. Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2021 Apr 1;96(4):E114-E117. doi:10.1002/ajh.26105. Epub 2021 Feb 26. PMID:33476436.
Tenold ME, Moskoff BN, Benjamin DJ, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA. Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center. Front Oncol. 2021 Mar 11;11:649209. doi:10.3389/fonc.2021.649209. PMID:33777810.
Pham B, Hoeg R, Krishnan R, Richman C, Tuscano J, Adobe M. Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome. Bone Marrow Transplant. 2021;56:2975–2980. doi:10.1038/s41409-021-01444-1.
Hoeg RT, Davis J, Jonas BA, Tuscano J , Rosenberg A, Abedi M. A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies. Clinical Lymphoma, Myeloma & Leukemia. 2020 July;20(7):453-458. Doi:10.1016/j.clml.2020.2.006.